<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37192595</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-0631</ISSN><JournalIssue CitedMedium="Internet"><Volume>246</Volume><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Pathology, research and practice</Title><ISOAbbreviation>Pathol Res Pract</ISOAbbreviation></Journal><ArticleTitle>COVID-19, post-acute COVID-19 syndrome (PACS, "long COVID") and post-COVID-19 vaccination syndrome (PCVS, "post-COVIDvac-syndrome"): Similarities and differences.</ArticleTitle><Pagination><StartPage>154497</StartPage><MedlinePgn>154497</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.prp.2023.154497</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0344-0338(23)00197-8</ELocationID><Abstract><AbstractText>Worldwide there have been over 760 million confirmed coronavirus disease 2019 (COVID-19) cases, and over 13 billion COVID-19 vaccine doses have been administered as of April 2023, according to the World Health Organization. An infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to an acute disease, i.e. COVID-19, but also to a post-acute COVID-19 syndrome (PACS, "long COVID"). Currently, the side effects of COVID-19 vaccines are increasingly being noted and studied. Here, we summarise the currently available indications and discuss our conclusions that (i) these side effects have specific similarities and differences to acute COVID-19 and PACS, that (ii) a new term should be used to refer to these side effects (post-COVID-19 vaccination syndrome, PCVS, colloquially "post-COVIDvac-syndrome"), and that (iii) there is a need to distinguish between acute COVID-19 vaccination syndrome (ACVS) and post-acute COVID-19 vaccination syndrome (PACVS) - in analogy to acute COVID-19 and PACS ("long COVID"). Moreover, we address mixed forms of disease caused by natural SARS-CoV-2 infection and COVID-19 vaccination. We explain why it is important for medical diagnosis, care and research to use the new terms (PCVS, ACVS and PACVS) in order to avoid confusion and misinterpretation of the underlying causes of disease and to enable optimal medical therapy. We do not recommend to use the term "Post-Vac-Syndrome" as it is imprecise. The article also serves to address the current problem of "medical gaslighting" in relation to PACS and PCVS by raising awareness among the medical professionals and supplying appropriate terminology for disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scholkmann</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland. Electronic address: Felix.Scholkmann@usz.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Christian-Albrecht</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Faculty of Medicine Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pathol Res Pract</MedlineTA><NlmUniqueID>7806109</NlmUniqueID><ISSNLinking>0344-0338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACVS</Keyword><Keyword MajorTopicYN="N">Acute COVID-19 vaccination syndrome</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PACS</Keyword><Keyword MajorTopicYN="N">PACVS</Keyword><Keyword MajorTopicYN="N">PCVS</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 vaccination syndrome</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 vaccination syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>19</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37192595</ArticleId><ArticleId IdType="pmc">PMC10154064</ArticleId><ArticleId IdType="doi">10.1016/j.prp.2023.154497</ArticleId><ArticleId IdType="pii">S0344-0338(23)00197-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Pneumonia of unknown cause &#x2013; China. 2020.</Citation></Reference><Reference><Citation>Wu F., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zsichla L., M&#xfc;ller V. Risk factors of severe COVID-19: a review of host, viral and environmental factors. Viruses. 2023;15(1):175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9863423</ArticleId><ArticleId IdType="pubmed">36680215</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y.D., et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercola J., Grant W.B., Wagner C.L. Evidence regarding vitamin D and risk of COVID-19 and its severity. Nutrients. 2020;12(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7692080</ArticleId><ArticleId IdType="pubmed">33142828</ArticleId></ArticleIdList></Reference><Reference><Citation>Radujkovic A., et al. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients. 2020;12(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551780</ArticleId><ArticleId IdType="pubmed">32927735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye K., et al. Does serum vitamin D level affect COVID-19 infection and its severity?-A case-control study. J. Am. Coll. Nutr. 2021;40(8):724&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">33048028</ArticleId></ArticleIdList></Reference><Reference><Citation>Abela I.A., et al. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. Nat. Commun. 2021;12(1):6703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8602384</ArticleId><ArticleId IdType="pubmed">34795285</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz S., et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ. Res. 2022;209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 2021;21(6):395&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082486</ArticleId><ArticleId IdType="pubmed">33927374</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., et al. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci. Rep. 2021;11(1):10902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner G.F., et al. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit. Care. 2020;24(1):657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682685</ArticleId><ArticleId IdType="pubmed">33228750</ArticleId></ArticleIdList></Reference><Reference><Citation>Schult D., et al. Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19. Gut Microbes. 2022;14(1):2031840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855857</ArticleId><ArticleId IdType="pubmed">35174781</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver A.K., et al. Environmental factors influencing COVID-19 incidence and severity. Annu Rev. Public Health. 2022;43:271&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10044492</ArticleId><ArticleId IdType="pubmed">34982587</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimohamadi Y., et al. Case fatality rate of COVID-19: a systematic review and meta-analysis. J. Prev. Med Hyg. 2021;62(2):E311&#x2013;E320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451339</ArticleId><ArticleId IdType="pubmed">34604571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., et al. Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: A world-wide review. J. Med Virol. 2023;95(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537802</ArticleId><ArticleId IdType="pubmed">36056540</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wei H., He D. Differences in case-fatality-rate of emerging SARS-CoV-2 variants. Public Health Pr. (Oxf. ) 2023;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741492</ArticleId><ArticleId IdType="pubmed">36532099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., et al. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metab. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="pubmed">37080828</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., et al. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C., et al. Proposed integrative model for post-COVID symptoms. Diabetes Metab. Syndr. 2021;15(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168334</ArticleId><ArticleId IdType="pubmed">34186367</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J., Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev. Med Virol. 2022;32(4)</Citation><ArticleIdList><ArticleId IdType="pubmed">34888989</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese J.T., et al. Generalisable long COVID subtypes: findings from the NIH N3C and recover programmes. EBioMedicine. 2023;87</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: an overview. Diabetes Metab. Syndr. 2021;15(3):869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A., et al. Long COVID classification: findings from a clustering analysis in the predi-COVID cohort study. Int J. Environ. Res Public Health. 2022;19(23)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9740149</ArticleId><ArticleId IdType="pubmed">36498091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C. Long COVID: current definition. Infection. 2021;50(1):285&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8438555</ArticleId><ArticleId IdType="pubmed">34519974</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., et al. Defining post-COVID symptoms (Post-Acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J. Environ. Res Public Health. 2021;18(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H. Covid-19 vaccines - immunity, variants, boosters. N. Engl. J. Med. 2022;387(11):1011&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O.J., et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 2022;22(9):1293&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Klement R.J., Walach H. SEIR models in the light of Critical Realism - a critique of exaggerated claims about the effectiveness of Covid 19 vaccinations. Futures. 2023;148</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9922436</ArticleId><ArticleId IdType="pubmed">36819658</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., et al. SARS-CoV-2 new variants: characteristic features and impact on the efficacy of different vaccines. Biomed. Pharm. 2021;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8433040</ArticleId><ArticleId IdType="pubmed">34562770</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooley N., et al. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. Infect. Dis. Ther. 2023:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9828372</ArticleId><ArticleId IdType="pubmed">36622633</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks P.W., Gruppuso P.A., Adashi E.Y. Urgent need for next-generation COVID-19 vaccines. JAMA. 2023;329(1):19&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">36484995</ArticleId></ArticleIdList></Reference><Reference><Citation>Azim Majumder M.A., Razzaque M.S. Repeated vaccination and 'vaccine exhaustion': relevance to the COVID-19 crisis. Expert Rev. Vaccin. 2022;21(8):1011&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">35475680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsumiyama K., Miyazaki Y., Shiozawa S. Self-organized criticality theory of autoimmunity. PLoS One. 2009;4(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795160</ArticleId><ArticleId IdType="pubmed">20046868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamandjou, C., et al., Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. medRxiv, 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10027956</ArticleId><ArticleId IdType="pubmed">36964001</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Bretones M., et al. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. J. Clin. Invest. 2023;133(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9797340</ArticleId><ArticleId IdType="pubmed">36594464</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado J.F., et al. SARS-CoV-2 spike protein vaccine-induced immune imprinting reduces nucleocapsid protein antibody response in SARS-CoV-2 infection. J. Immunol. Res. 2022;2022:8287087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9355782</ArticleId><ArticleId IdType="pubmed">35935586</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F.X., et al. Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. iScience. 2022;25(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9625849</ArticleId><ArticleId IdType="pubmed">36338436</ArticleId></ArticleIdList></Reference><Reference><Citation>Offit P.A. Bivalent covid-19 vaccines - a cautionary tale. N. Engl. J. Med. 2023;388(6):481&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">36630616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu J., et al. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Sci. Rep. 2022;12(1):15612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9481526</ArticleId><ArticleId IdType="pubmed">36114224</ArticleId></ArticleIdList></Reference><Reference><Citation>Irrgang P., et al. Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 2022:eade2798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847566</ArticleId><ArticleId IdType="pubmed">36548397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchini R., et al. IgG4 drives M2a macrophages to a regulatory M2b-like phenotype: potential implication in immune tolerance. Allergy. 2019;74(3):483&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492166</ArticleId><ArticleId IdType="pubmed">30338531</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiravi A.A., et al. Cardiovascular complications of SARS-CoV-2 vaccines: an overview. Cardiol. Ther. 2022;11(1):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629102</ArticleId><ArticleId IdType="pubmed">34845662</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmas C., et al. Post-mRNA COVID-19 vaccines myocarditis: not so rare in cardiology practice. Arch. Cardiovasc. Dis. Suppl. 2023;15(1):48.</Citation></Reference><Reference><Citation>Almas T., et al. Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: a state-of-the-heart review. Biomed. Pharmacother. 2022;149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934717</ArticleId><ArticleId IdType="pubmed">35325848</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., et al. Cardiovascular complications of COVID-19 vaccines. Front Cardiovasc Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8971371</ArticleId><ArticleId IdType="pubmed">35369340</ArticleId></ArticleIdList></Reference><Reference><Citation>Song T.J., et al. Cerebral venous thrombosis after ChAdOx1 nCoV-19 vaccination: a systematic review. Eur. Rev. Med Pharm. Sci. 2023;27(1):404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">36647889</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol. Scand. 2022;145(1):5&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653194</ArticleId><ArticleId IdType="pubmed">34750810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriwastava S., et al. COVID-19 vaccination and neurological manifestations: a review of case reports and case series. Brain Sci. 2022;12(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8946610</ArticleId><ArticleId IdType="pubmed">35326363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang K., Lee S.Y., Lee D.C. Neuro-ophthalmologic symptoms after coronavirus disease 2019 vaccination: a retrospective study. BMC Ophthalmol. 2023;23(1):11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9813886</ArticleId><ArticleId IdType="pubmed">36604664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu S.-N., et al. Changes of ECG parameters after BNT162b2 vaccine in the senior high school students. Eur. J. Pediatr. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9813456</ArticleId><ArticleId IdType="pubmed">36602621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez Y., et al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J. Autoimmun. 2022;132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9399140</ArticleId><ArticleId IdType="pubmed">36041291</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron P. Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management. Endocrine. 2022;78(3):406&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9243876</ArticleId><ArticleId IdType="pubmed">35763241</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara L.J., et al. Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Clin. Rheuma. 2022;41(5):1603&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8979721</ArticleId><ArticleId IdType="pubmed">35378658</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirmosayyeb O., et al. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: a systematic review. Rev. Neurol. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844421</ArticleId><ArticleId IdType="pubmed">36658048</ArticleId></ArticleIdList></Reference><Reference><Citation>Gips J.R., Woreta T.A. It can't be a coincidence: a comparison of cases of autoimmune hepatitis after vaccination against COVID-19. ACG Case Rep. J. 2023;10(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9891451</ArticleId><ArticleId IdType="pubmed">36743330</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimohamadi Y., et al. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J. Prev. Med Hyg. 2020;61(3):E304&#x2013;E312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595075</ArticleId><ArticleId IdType="pubmed">33150219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., et al. Longitudinal symptom dynamics of COVID-19 infection. Nat. Commun. 2020;11(1):6208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7718370</ArticleId><ArticleId IdType="pubmed">33277494</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.G., Qin L., Puah S.H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J. Aust. 2020;213(2):54&#x2013;56 e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361309</ArticleId><ArticleId IdType="pubmed">32572965</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir. Med. 2020;8(12):1201&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834127</ArticleId><ArticleId IdType="pubmed">32861276</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M., et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat. Commun. 2022;13(1):6856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9651890</ArticleId><ArticleId IdType="pubmed">36369151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Tov A., et al. Dynamics in COVID-19 symptoms during different waves of the pandemic among children infected with SARS-CoV-2 in the ambulatory setting. Eur. J. Pedia. 2022;181(9):3309&#x2013;3318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9395901</ArticleId><ArticleId IdType="pubmed">35778524</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C., et al. Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with wuhan, alpha or delta SARS-CoV-2 variant. Pathogens. 2022;11(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzid D., et al. Comparison of patients infected with delta versus omicron COVID-19 variants presenting to paris emergency departments: a retrospective cohort study. Ann. Intern Med. 2022;175(6):831&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941485</ArticleId><ArticleId IdType="pubmed">35286147</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond. ) 2021;53(10):737&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera Martimbianco A.L., et al. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review. Int J. Clin. Pr. 2021;75(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., et al. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam. Pr. 2022;39(1):159&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes D.L., et al. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. 2021;199(2):113&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Post COVID-19 condition (Long COVID). 2022.</Citation></Reference><Reference><Citation>CDC Long COVID or Post-COVID Conditions. 2022.</Citation></Reference><Reference><Citation>Fernandez-de-Las-Penas C., et al. Post-COVID-19 symptoms 2 years after SARS-CoV-2 infection among hospitalized vs nonhospitalized patients. JAMA Netw. Open. 2022;5(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667330</ArticleId><ArticleId IdType="pubmed">36378309</ArticleId></ArticleIdList></Reference><Reference><Citation>Stormorken E., Jason L.A., Kirkevold M. Fatigue in adults with post-infectious fatigue syndrome: a qualitative content analysis. BMC Nurs. 2015;14:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662830</ArticleId><ArticleId IdType="pubmed">26617466</ArticleId></ArticleIdList></Reference><Reference><Citation>Salit I.E. Post-infectious fatigue. Can. Fam. Physician. 1987;33:1217&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2218522</ArticleId><ArticleId IdType="pubmed">21263931</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessely S. History of postviral fatigue syndrome. Br. Med Bull. 1991;47(4):919&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">1794091</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannister B.A. Post-infectious disease syndrome. Post. Med J. 1988;64(753):559&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2428896</ArticleId><ArticleId IdType="pubmed">3074289</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J., et al. Unexplained post-acute infection syndromes. Nat. Med. 2022;28(5):911&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng M.P., et al. Does influenza A infection increase oxidative damage? Antioxid. Redox Signal. 2014;21(7):1025&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pubmed">24673169</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus P., et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine. 2015;33(46):6173&#x2013;6177.</Citation><ArticleIdList><ArticleId IdType="pubmed">26475444</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallings R. A case of chronic fatigue syndrome triggered by influenza H1N1 (swine influenza) J. Clin. Pathol. 2010;63(2):184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">19858526</ArticleId></ArticleIdList></Reference><Reference><Citation>Seet R.C., Quek A.M., Lim E.C. Post-infectious fatigue syndrome in dengue infection. J. Clin. Virol. 2007;38(1):1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17137834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigera P.C., et al. Dengue and post-infection fatigue: findings from a prospective cohort-the Colombo Dengue Study. Trans. R. Soc. Trop. Med Hyg. 2021;115(6):669&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115379</ArticleId><ArticleId IdType="pubmed">33099653</ArticleId></ArticleIdList></Reference><Reference><Citation>Furberg M., Anticona C., Schumann B. Post-infectious fatigue following Puumala virus infection. Infect. Dis. (Lond. ) 2019;51(7):519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">31081420</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen I., et al. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. QJM. 2006;99(1):49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330509</ArticleId></ArticleIdList></Reference><Reference><Citation>White P.D., et al. The nosology of sub-acute and chronic fatigue syndromes that follow infectious mononucleosis. Psychol. Med. 2004;34(3):499&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">15259835</ArticleId></ArticleIdList></Reference><Reference><Citation>White P.D., et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br. J. Psychiatry. 1998;173:475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">9926075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen M., et al. Predictors of chronic fatigue in adolescents six months after acute Epstein-Barr virus infection: A prospective cohort study. Brain Behav. Immun. 2019;75:94&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">30261303</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia J., et al. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J. Clin. Pathol. 2010;63(2):165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">19828908</ArticleId></ArticleIdList></Reference><Reference><Citation>Seishima M., et al. Chronic fatigue syndrome after human parvovirus B19 infection without persistent viremia. Dermatology. 2008;216(4):341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">18277075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bujak D.I., Weinstein A., Dornbush R.L. Clinical and neurocognitive features of the post Lyme syndrome. J. Rheuma. 1996;23(8):1392&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8856619</ArticleId></ArticleIdList></Reference><Reference><Citation>Picha D., et al. Symptoms of post-Lyme syndrome in long-term outcome of patients with neuroborreliosis. Scand. J. Infect. Dis. 2006;38(8):747&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857637</ArticleId></ArticleIdList></Reference><Reference><Citation>Treib J., et al. Chronic fatigue syndrome in patients with Lyme borreliosis. Eur. Neurol. 2000;43(2):107&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudino E.A., Coyle P.K., Krupp L.B. Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences. Arch. Neurol. 1997;54(11):1372&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">9362985</ArticleId></ArticleIdList></Reference><Reference><Citation>Morroy G., et al. Fatigue following acute Q-fever: a systematic literature review. PLoS One. 2016;11(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880326</ArticleId><ArticleId IdType="pubmed">27223465</ArticleId></ArticleIdList></Reference><Reference><Citation>Morch K., et al. Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after. BMC Infect. Dis. 2009;9:206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808308</ArticleId><ArticleId IdType="pubmed">20003489</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunskar G.S., et al. The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years after Giardia infection. A historic cohort study. Scand. J. Gastroenterol. 2012;47(8&#x2013;9):956&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">22746290</ArticleId></ArticleIdList></Reference><Reference><Citation>Naess H., et al. Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, disability and long-term sickness absence. BMC Gastroenterol. 2012;12:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292445</ArticleId><ArticleId IdType="pubmed">22316329</ArticleId></ArticleIdList></Reference><Reference><Citation>Morch K., et al. Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course. BMC Gastroenterol. 2013;13:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598369</ArticleId><ArticleId IdType="pubmed">23399438</ArticleId></ArticleIdList></Reference><Reference><Citation>Stormorken E., Jason L.A., Kirkevold M. From good health to illness with post-infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory. BMC Fam. Pr. 2017;18(1):49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5369194</ArticleId><ArticleId IdType="pubmed">28347294</ArticleId></ArticleIdList></Reference><Reference><Citation>Litleskare S., et al. Prevalence of irritable bowel syndrome and chronic fatigue 10 years after giardia infection. Clin. Gastroenterol. Hepatol. 2018;16(7):1064&#x2013;1072 e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29378314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wensaas K.A., et al. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 2012;61(2):214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">21911849</ArticleId></ArticleIdList></Reference><Reference><Citation>Aucott J.N., et al. Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: a prospective cohort study. Int J. Infect. Dis. 2022;116:230&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">35066160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadick N.A., et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann. Intern Med. 1994;121(8):560&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">8085687</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebman A.W., et al. The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment lyme disease syndrome. Front Med (Lausanne) 2017;4:224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5735370</ArticleId><ArticleId IdType="pubmed">29312942</ArticleId></ArticleIdList></Reference><Reference><Citation>Geebelen L., et al. Non-specific symptoms and post-treatment Lyme disease syndrome in patients with Lyme borreliosis: a prospective cohort study in Belgium (2016-2020) BMC Infect. Dis. 2022;22(1):756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9518937</ArticleId><ArticleId IdType="pubmed">36171561</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal G., Yadav S., Kumar R. Post-intensive care syndrome: an overview. J. Transl. Int Med. 2017;5(2):90&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506407</ArticleId><ArticleId IdType="pubmed">28721340</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue S., et al. Post-intensive care syndrome: its pathophysiology, prevention, and future directions. Acute Med Surg. 2019;6(3):233&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6603316</ArticleId><ArticleId IdType="pubmed">31304024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M., Kang J., Jeong Y.J. Risk factors for post-intensive care syndrome: a systematic review and meta-analysis. Aust. Crit. Care. 2020;33(3):287&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">31839375</ArticleId></ArticleIdList></Reference><Reference><Citation>Colbenson G.A., Johnson A., Wilson M.E. Post-intensive care syndrome: impact, prevention, and management. Breathe (Sheff. ) 2019;15(2):98&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544795</ArticleId><ArticleId IdType="pubmed">31191717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramnarain D., et al. Post Intensive Care Syndrome (PICS): an overview of the definition, etiology, risk factors, and possible counseling and treatment strategies. Expert Rev. Neurother. 2021;21(10):1159&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pubmed">34519235</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau A.F., et al. Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic. Ann. Intensive Care. 2021;11(1):118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319705</ArticleId><ArticleId IdType="pubmed">34324073</ArticleId></ArticleIdList></Reference><Reference><Citation>Biehl M., Sese D. Post-intensive care syndrome and COVID-19 - implications post pandemic. Cleve Clin. J. Med. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32759175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi N., et al. Post-intensive care syndrome and its new challenges in coronavirus disease 2019 (COVID-19) pandemic: a review of recent advances and perspectives. J. Clin. Med. 2021;10(17)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432235</ArticleId><ArticleId IdType="pubmed">34501316</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanwani-Nanwani K., et al. Prevalence of post-intensive care syndrome in mechanically ventilated patients with COVID-19. Sci. Rep. 2022;12(1):7977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9105588</ArticleId><ArticleId IdType="pubmed">35562379</ArticleId></ArticleIdList></Reference><Reference><Citation>Daste C., et al. Post-intensive care syndrome in patients surviving COVID-19. Ann. Phys. Rehabil. Med. 2021;64(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233854</ArticleId><ArticleId IdType="pubmed">34182168</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardashkhani S., et al. Post-intensive care syndrome in covid-19 patients discharged from the intensive care unit. J. Hosp. Palliat. Nurs. 2021;23(6):530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8560146</ArticleId><ArticleId IdType="pubmed">34534991</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffri A., Jaffri U.A. Post-intensive care syndrome and COVID-19: crisis after a crisis? Heart Lung. 2020;49(6):883&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301100</ArticleId><ArticleId IdType="pubmed">32690219</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazmi A., et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8235009</ArticleId><ArticleId IdType="pubmed">34207394</ArticleId></ArticleIdList></Reference><Reference><Citation>Riad A., et al. Prevalence of COVID-19 vaccine side effects among healthcare workers in the czech republic. J. Clin. Med. 2021;10(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8037149</ArticleId><ArticleId IdType="pubmed">33916020</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty A.L., et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw. Open. 2021;4(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8696570</ArticleId><ArticleId IdType="pubmed">34935921</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed B.Q., et al. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J. Infect. Dis. 2021;111:219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351310</ArticleId><ArticleId IdType="pubmed">34384899</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Hammad O., et al. Side effects reported by jordanian healthcare workers who received COVID-19 vaccines. Vaccines. 2021;9(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228820</ArticleId><ArticleId IdType="pubmed">34205917</ArticleId></ArticleIdList></Reference><Reference><Citation>Klugar M., et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among german healthcare workers. Biology. 2021;10(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389568</ArticleId><ArticleId IdType="pubmed">34439984</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shitany N.A., et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among saudi residents: a retrospective cross-sectional study. Int J. Gen. Med. 2021;14:1389&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8068468</ArticleId><ArticleId IdType="pubmed">33907443</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgendy M.O., et al. Side effects and efficacy of COVID-19 vaccines among the egyptian population. Vaccin. (Basel) 2022;10(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779934</ArticleId><ArticleId IdType="pubmed">35062770</ArticleId></ArticleIdList></Reference><Reference><Citation>Omeish H., et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum. Vaccin Immunother. 2022;18(1):1981086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920252</ArticleId><ArticleId IdType="pubmed">34614383</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., et al. The safety profile of COVID-19 vaccinations in the United States. Am. J. Infect. Control. 2022;50(1):15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8539830</ArticleId><ArticleId IdType="pubmed">34699960</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 2022;22(7):1002&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993156</ArticleId><ArticleId IdType="pubmed">35405090</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro Ben David S., et al. Immediate side effects of Comirnaty COVID-19 vaccine: a nationwide survey of vaccinated people in Israel, December 2020 to March 2021. Eur. Surveill. 2022;27(13)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8973016</ArticleId><ArticleId IdType="pubmed">35362408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq H.A., et al. A review of adverse effects of COVID-19 vaccines. Infez. Med. 2022;30(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929726</ArticleId><ArticleId IdType="pubmed">35350266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause A.M., et al. Safety monitoring of COVID-19 vaccine booster doses among adults - United States, September 22, 2021-February 6, 2022. MMWR Morb. Mortal. Wkly Rep. 2022;71(7):249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853473</ArticleId><ArticleId IdType="pubmed">35176008</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira E.D., Jr., et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N. Engl. J. Med. 2022;386(20):1910&#x2013;1921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprent J., King C. COVID-19 vaccine side effects: the positives about feeling bad. Sci. Immunol. 2021;6(60)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9267253</ArticleId><ArticleId IdType="pubmed">34158390</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanzio M., et al. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: a systematic review. Lancet Reg. Health Eur. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553263</ArticleId><ArticleId IdType="pubmed">34729549</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltezou H.C., et al. Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Vaccine. 2022;40(2):183&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626274</ArticleId><ArticleId IdType="pubmed">34863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxi N., et al. Allergic reactions to COVID-19 vaccines: risk factors, frequency, mechanisms and management. BioDrugs. 2022;36(4):443&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9190452</ArticleId><ArticleId IdType="pubmed">35696066</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghimi S.M. Allergic reactions and anaphylaxis to LNP-Based COVID-19 vaccines. Mol. Ther. 2021;29(3):898&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862013</ArticleId><ArticleId IdType="pubmed">33571463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobczak M., Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin. Mol. Allergy. 2022;20(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8762434</ArticleId><ArticleId IdType="pubmed">35039051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E., et al. Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021. Eur. Surveill. 2021;26(33)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380974</ArticleId><ArticleId IdType="pubmed">34414880</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro T.T., Cole M., Su J.R. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890485</ArticleId><ArticleId IdType="pubmed">33576785</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaishi T., et al. Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan. Sci. Rep. 2022;12(1):15510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9476447</ArticleId><ArticleId IdType="pubmed">36109582</ArticleId></ArticleIdList></Reference><Reference><Citation>CDHP California State Epidemiologist Statement Recommending Providers Pause Administration of Single Lot of Moderna COVID-19 Vaccine. 2021.</Citation></Reference><Reference><Citation>Shim E., Choi W., Song Y. Clinical time delay distributions of COVID-19 in 2020&#x2013;2022 in the Republic of Korea: inferences from a nationwide database analysis. J. Clin. Med. 2022;11(12):3269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225637</ArticleId><ArticleId IdType="pubmed">35743340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward T., Johnsen A. Understanding an evolving pandemic: an analysis of the clinical time delay distributions of COVID-19 in the United Kingdom. PLoS One. 2021;16(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8528322</ArticleId><ArticleId IdType="pubmed">34669712</ArticleId></ArticleIdList></Reference><Reference><Citation>VAERS. Vaccine Adverse Event Reporting System. 2023 [cited accessed January 2023; Available from: &#x3008;https://vaers.hhs.gov/&#x3009;.</Citation></Reference><Reference><Citation>Patone M., et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 2021;28(2):410&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863574</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId></ArticleIdList></Reference><Reference><Citation>Halushka M.K., Vander Heide R.S. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol. 2021;50</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583586</ArticleId><ArticleId IdType="pubmed">33132119</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawalha K., et al. Systematic review of COVID-19 related myocarditis: insights on management and outcome. Cardiovasc Revasc Med. 2021;23:107&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434380</ArticleId><ArticleId IdType="pubmed">32847728</ArticleId></ArticleIdList></Reference><Reference><Citation>Haussner W., et al. COVID-19 associated myocarditis: a systematic review. Am. J. Emerg. Med. 2022;51:150&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531234</ArticleId><ArticleId IdType="pubmed">34739868</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore S.S., et al. Myocarditis associated with Covid-19 disease: a systematic review of published case reports and case series. Int J. Clin. Pr. 2021;75(11)</Citation><ArticleIdList><ArticleId IdType="pubmed">34235815</ArticleId></ArticleIdList></Reference><Reference><Citation>Castiello T., et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2022;27(1):251&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7988375</ArticleId><ArticleId IdType="pubmed">33761041</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal V., et al. COVID-19 infection and myocarditis: a state-of-the-art systematic review. J. Prim. Care Community Health. 2021;12 p. 21501327211056800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647231</ArticleId><ArticleId IdType="pubmed">34854348</ArticleId></ArticleIdList></Reference><Reference><Citation>Okor I., et al. COVID-19 myocarditis: an emerging clinical conundrum. Curr. Probl. Cardiol. 2022;47(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135640</ArticleId><ArticleId IdType="pubmed">35644500</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban S., et al. COVID-19 related myocarditis in adults: a systematic review of case reports. J. Clin. Med. 2022;11(19)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9573317</ArticleId><ArticleId IdType="pubmed">36233389</ArticleId></ArticleIdList></Reference><Reference><Citation>Power J.R., Keyt L.K., Adler E.D. Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations. Expert Rev. Cardiovasc. Ther. 2022;20(4):241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115793</ArticleId><ArticleId IdType="pubmed">35414326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilonze O.J., Guglin M.E. Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 2021. Heart Fail Rev. 2022;27(6):2033&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9023259</ArticleId><ArticleId IdType="pubmed">35449353</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M., et al. Development of myocarditis and pericarditis after COVID-19 vaccination in children and adolescents: a systematic review. Clin. Cardiol. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10018089</ArticleId><ArticleId IdType="pubmed">36594165</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D.Y., et al. Myocarditis after COVID&#x2010;19 mRNA vaccination: a systematic review of case reports and case series. Clin. Cardiol. 2022;45(7):691&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286338</ArticleId><ArticleId IdType="pubmed">35652390</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M., et al. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: a systematic review. Ann. Med Surg. (Lond. ) 2022;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8912977</ArticleId><ArticleId IdType="pubmed">35291413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S.K., et al. Global reports of myocarditis following COVID-19 vaccination: a systematic review and meta-analysis. Diabetes Metab. Syndr. 2022;16(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135698</ArticleId><ArticleId IdType="pubmed">35660931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane S., Yeomans A., Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open. 2022;12(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133727</ArticleId><ArticleId IdType="pubmed">35613761</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., et al. Myocarditis or pericarditis following the COVID-19 vaccination in adolescents: a systematic review. Vaccines. 2022;10(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9412657</ArticleId><ArticleId IdType="pubmed">36016204</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidecker B., et al. Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. Eur. J. Heart Fail. 2022;24(11):2000&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538893</ArticleId><ArticleId IdType="pubmed">36065751</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassar M., et al. COVID-19 vaccine-induced myocarditis: case report with literature review. Diabetes Metab. Syndr. 2021;15(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270733</ArticleId><ArticleId IdType="pubmed">34293552</ArticleId></ArticleIdList></Reference><Reference><Citation>Matar R.H., et al. Clinical characteristics of patients with myocarditis following COVID-19 mRNA vaccination: a systematic review and meta-analysis. J. Clin. Med. 2022;11:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9369856</ArticleId><ArticleId IdType="pubmed">35956137</ArticleId></ArticleIdList></Reference><Reference><Citation>Piche-Renaud P.P., Morris S.K., Top K.A. A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination. Br. J. Clin. Pharm. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878271</ArticleId><ArticleId IdType="pubmed">36480113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.H., et al. COVID-19 vaccine-related myocarditis: a descriptive study of 40 case reports. Cureus. 2022;14(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8887934</ArticleId><ArticleId IdType="pubmed">35251812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatziantoniou S., et al. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States. Expert Rev. Vaccin. 2022;21(11):1691&#x2013;1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">35815358</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazlollahi A., et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev. Med Virol. 2022;32(4)</Citation><ArticleIdList><ArticleId IdType="pubmed">34921468</ArticleId></ArticleIdList></Reference><Reference><Citation>Furqan M., et al. COVID-19 vaccine-related myocardial and pericardial inflammation. Curr. Cardiol. Rep. 2022;24(12):2031&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9703393</ArticleId><ArticleId IdType="pubmed">36441403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling R.R., et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir. Med. 2022;10(7):679&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9000914</ArticleId><ArticleId IdType="pubmed">35421376</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal M., et al. Myocarditis post SARS-CoV-2 vaccination: a systematic review. QJM. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903459</ArticleId><ArticleId IdType="pubmed">35238384</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh T.H., et al. Clinical features of patients presenting to the emergency department with cardiovascular adverse reactions after COVID-19 mRNA vaccination. J. Korean Med Sci. 2022;37(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901880</ArticleId><ArticleId IdType="pubmed">35257528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam N., et al. A late presentation of COVID-19 vaccine-induced myocarditis. Cureus. 2021;13(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504680</ArticleId><ArticleId IdType="pubmed">34660088</ArticleId></ArticleIdList></Reference><Reference><Citation>Morz M. A case report: multifocal necrotizing encephalitis and myocarditis after BNT162b2 mRNA vaccination against COVID-19. Vaccines. 2022;10(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9611676</ArticleId><ArticleId IdType="pubmed">36298516</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumeier C., et al. Intramyocardial inflammation after COVID-19 vaccination: an endomyocardial biopsy-proven case series. Int J. Mol. Sci. 2022;23(13)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9266869</ArticleId><ArticleId IdType="pubmed">35805941</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M., et al. Persistent varicella zoster virus infection following mRNA COVID &#x2010;19 vaccination was associated with the presence of encoded spike protein in the lesion. J. Cutan. Immunol. Allergy. 2022;6(1):18&#x2013;23.</Citation></Reference><Reference><Citation>Schulte E.C., et al. Systematic review of cases of acute myelitis in individuals with COVID-19. Eur. J. Neurol. 2021;28(10):3230&#x2013;3244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239542</ArticleId><ArticleId IdType="pubmed">34060708</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Escobar M.C., et al. Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: a case report and review of literature. J. Neuroimmunol. 2021;353</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7895682</ArticleId><ArticleId IdType="pubmed">33640717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail, Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J. Neurol. 2022;269(2):541&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8359762</ArticleId><ArticleId IdType="pubmed">34386902</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamec I., et al. Transverse myelitis following COVID-19: Insights from a multi-center study and systematic literature review. J. Neurol. Sci. 2022;443</Citation><ArticleIdList><ArticleId IdType="pubmed">36334503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudlavalleti A., Nath A. Clinical profile and outcomes of COVID-19-associated transverse myelitis: a case report and review of literature. Neurol. Clin. Pr. 2022;12(6):e221&#x2013;e227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9757108</ArticleId><ArticleId IdType="pubmed">36540137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed J.O., et al. Post COVID-19 neurological complications; a meta-analysis. Ann. Med Surg. (Lond. ) 2022;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891214</ArticleId><ArticleId IdType="pubmed">35261766</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S.A., et al. Post COVID-19 transverse myelitis; a case report with review of literature. Ann. Med Surg. (Lond. ) 2021;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380545</ArticleId><ArticleId IdType="pubmed">34457267</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroufi S.F., et al. Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature. Hum. Vaccin Immunother. 2022;18(1):2040239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9009891</ArticleId><ArticleId IdType="pubmed">35240927</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano H., et al. Acute transverse myelitis after BNT162b2 vaccination against COVID-19: Report of a fatal case and review of the literature. J. Neurol. Sci. 2022;434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8685167</ArticleId><ArticleId IdType="pubmed">34953348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostovan V.R., et al. Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: a systematic review. Mult. Scler. Relat. Disord. 2022;66</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258415</ArticleId><ArticleId IdType="pubmed">35858499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriwastava S., et al. Spectrum of neuroimaging findings in Post-COVID-19 vaccination: a case series and review of literature. Neurol. Int. 2021;13(4):622&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628885</ArticleId><ArticleId IdType="pubmed">34842783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail, Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J. Neuroimmunol. 2022;362</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577051</ArticleId><ArticleId IdType="pubmed">34839149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao Y.T., et al. Acute transverse myelitis after COVID-19 vaccination. Med. (Kaunas. ) 2021;57(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8540274</ArticleId><ArticleId IdType="pubmed">34684047</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman G.C., et al. Acute transverse myelitis (ATM):clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222) Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8107358</ArticleId><ArticleId IdType="pubmed">33981305</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan E., et al. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J. Neurol. 2022;269(3):1121&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8418691</ArticleId><ArticleId IdType="pubmed">34482455</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago F., et al. Human herpesvirus&#x2010;6, &#x2010;7, and Epstein&#x2010;Barr virus reactivation in pityriasis rosea during COVID&#x2010;19. J. Med. Virol. 2020;93(4):1850&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537064</ArticleId><ArticleId IdType="pubmed">32970319</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A., et al. High incidence of Epstein&#x2013;Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect. Dis. Now. 2021;51(3):296&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R., et al. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br. J. Dermatol. 2020;183(6):1145&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436688</ArticleId><ArticleId IdType="pubmed">32790074</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B., et al. Epstein-barr virus and human herpesvirus-6 reactivation in acute COVID-19 patients. Viruses. 2022;14(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504756</ArticleId><ArticleId IdType="pubmed">36146679</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., et al. Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation. BMC Infect. Dis. 2021;21(1):955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441951</ArticleId><ArticleId IdType="pubmed">34525962</ArticleId></ArticleIdList></Reference><Reference><Citation>Algaadi S.A. Herpes zoster and COVID-19 infection: a coincidence or a causal relationship? Infection. 2022;50(2):289&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607065</ArticleId><ArticleId IdType="pubmed">34807403</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz J., Yue S., Xue W. Herpes simplex and herpes zoster viruses in COVID-19 patients. Ir. J. Med Sci. 2022;191(3):1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8272836</ArticleId><ArticleId IdType="pubmed">34247308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pona A., et al. Herpes zoster as a potential complication of coronavirus disease 2019. Dermatol. Ther. 2020;33(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361152</ArticleId><ArticleId IdType="pubmed">32602610</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Balc'h P., et al. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit. Care. 2020;24(1):530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453668</ArticleId><ArticleId IdType="pubmed">32859241</ArticleId></ArticleIdList></Reference><Reference><Citation>Saade A., et al. Herpesvirus reactivation during severe COVID-19 and high rate of immune defect. Infect. Dis. Now. 2021;51(8):676&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317452</ArticleId><ArticleId IdType="pubmed">34332165</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathy R.A., et al. Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry. J. Eur. Acad. Dermatol. Venereol. 2022;36(1):e6&#x2013;e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656951</ArticleId><ArticleId IdType="pubmed">34487581</ArticleId></ArticleIdList></Reference><Reference><Citation>Gringeri M., et al. Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis. Expert Rev. Vaccin. 2022;21(5):675&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">35191364</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid E., et al. Herpes zoster emergence following mRNA COVID-19 vaccine. J. Med. Virol. 2021;93(9):5231&#x2013;5232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242521</ArticleId><ArticleId IdType="pubmed">33913545</ArticleId></ArticleIdList></Reference><Reference><Citation>Birabaharan M., Kaelber D.C., Karris M.Y. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: A cohort study. J. Am. Acad. Dermatol. 2022;87(3):649&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8608757</ArticleId><ArticleId IdType="pubmed">34826538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu C.W., et al. Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis. Expert Rev. Vaccin. 2022;21(5):601&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">35112938</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsikas Triantafyllidis K., et al. Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports. Vaccines. 2021;9(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8471236</ArticleId><ArticleId IdType="pubmed">34579250</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai H.D., et al. Can SARS-CoV-2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review. J. Cosmet. Dermatol. 2021;20(11):3350&#x2013;3361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597588</ArticleId><ArticleId IdType="pubmed">34719084</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzum A., et al. Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report. Clin. Exp. Vaccin. Res. 2022;11(2):222&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200649</ArticleId><ArticleId IdType="pubmed">35799871</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluss M., et al. Case report: cytomegalovirus reactivation and pericarditis following ChAdOx1 nCoV-19 vaccination against SARS-CoV-2. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803643</ArticleId><ArticleId IdType="pubmed">35116025</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., et al. Investigation of long COVID prevalence and its relationship to epstein-barr virus reactivation. Pathogens. 2021;10(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanff T.C., et al. Thrombosis in COVID-19. Am. J. Hematol. 2020;95(12):1578&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674272</ArticleId><ArticleId IdType="pubmed">32857878</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ani F., Chehade S., Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb. Res. 2020;192:152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255332</ArticleId><ArticleId IdType="pubmed">32485418</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen J.D., Stevens H., Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ. Res. 2020;127(4):571&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386875</ArticleId><ArticleId IdType="pubmed">32586214</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh Y.J., et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2021;298(2):E70&#x2013;E80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745997</ArticleId><ArticleId IdType="pubmed">33320063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dakay K., et al. Cerebral venous sinus thrombosis in COVID-19 infection: a case series and review of the literature. J. Stroke Cereb. Dis. 2021;30(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833244</ArticleId><ArticleId IdType="pubmed">33190109</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J., et al. Thrombotic complications of COVID-19. Am. J. Emerg. Med. 2021;39:213&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7528743</ArticleId><ArticleId IdType="pubmed">33036855</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020;191:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu T.M., et al. Cerebral venous thrombosis in patients with COVID-19 infection: a case series and systematic review. J. Stroke Cereb. Dis. 2020;29(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538072</ArticleId><ArticleId IdType="pubmed">33254369</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdalkader M., et al. Cerebral venous sinus thrombosis in COVID-19 patients: a multicenter study and review of literature. J. Stroke Cereb. Dis. 2021;30(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931726</ArticleId><ArticleId IdType="pubmed">33743411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh R., et al. Cerebral venous thrombosis in COVID-19. Diabetes Metab. Syndr. 2021;15(3):1039&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128714</ArticleId><ArticleId IdType="pubmed">34015627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner W.J., Gorog D.A. Incidence of thrombotic complications in COVID-19: on behalf of ICODE: the International COVID-19 Thrombosis Biomarkers Colloquium. J. Thromb. Thrombolysis. 2021;52(4):999&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161345</ArticleId><ArticleId IdType="pubmed">34047938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M.A.M., Spinler S.A. COVID-19 and thrombosis: from bench to bedside. Trends Cardiovasc Med. 2021;31(3):143&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836332</ArticleId><ArticleId IdType="pubmed">33338635</ArticleId></ArticleIdList></Reference><Reference><Citation>Poor H.D. Pulmonary thrombosis and thromboembolism in COVID-19. Chest. 2021;160(4):1471&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213519</ArticleId><ArticleId IdType="pubmed">34153340</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicherla C.B., et al. Cerebral venous sinus thrombosis in the COVID-19 pandemic. J. Neuroophthalmol. 2020;40(4):457&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">33186264</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M., Hunt B.J. Thrombosis and coagulopathy in COVID-19: an illustrated review. Res Pr. Thromb. Haemost. 2020;4(5):744&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7354416</ArticleId><ArticleId IdType="pubmed">32685883</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilotta C., et al. COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8666479</ArticleId><ArticleId IdType="pubmed">34912330</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazete C., et al. Thrombotic events and COVID-19 vaccines. Int J. Tube Lung Dis. 2021;25(9):701&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412105</ArticleId><ArticleId IdType="pubmed">34802491</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobaiqy M., et al. Thrombotic adverse events reported for moderna, pfizer and oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the eudravigilance database. Vaccines. 2021;9(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8624459</ArticleId><ArticleId IdType="pubmed">34835256</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Post-SARS-CoV-2 vaccination thrombosis is frequent and ubiquitous. Indian J. Ophthalmol. 2022;70(5):1864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9333013</ArticleId><ArticleId IdType="pubmed">35502110</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., et al. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT) Semin Hematol. 2022;59(2):97&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863951</ArticleId><ArticleId IdType="pubmed">35512907</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 2021;384(22):2092&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. J. Thromb. Haemost. 2022;20(1):149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646430</ArticleId><ArticleId IdType="pubmed">34693641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S.H., et al. Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: a narrative review. Ann. Med Surg. (Lond. ) 2022;73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556865</ArticleId><ArticleId IdType="pubmed">34745596</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchandot B., et al. Vaccine-induced immune thrombotic thrombocytopenia: current evidence, potential mechanisms, clinical implications, and future directions. Eur. Heart J. Open. 2021;1(2):oeab014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385852</ArticleId><ArticleId IdType="pubmed">35915769</ArticleId></ArticleIdList></Reference><Reference><Citation>Elberry M.H., et al. A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines. J. Thromb. Thrombolysis. 2022;53(4):798&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853120</ArticleId><ArticleId IdType="pubmed">35157188</ArticleId></ArticleIdList></Reference><Reference><Citation>Saluja P., et al. Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: a systematic review of reported cases. Thromb. Res. 2022;214:115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060716</ArticleId><ArticleId IdType="pubmed">35533526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines D.B., Greinacher A. Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT) Blood. 2023</Citation></Reference><Reference><Citation>Schonborn L., Greinacher A. Longitudinal aspects of VITT. Semin Hematol. 2022;59(2):108&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8898788</ArticleId><ArticleId IdType="pubmed">35512899</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya S., et al. Unique case of central retinal artery occlusion secondary to COVID-19 disease. IDCases. 2020;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301806</ArticleId><ArticleId IdType="pubmed">32572363</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Abri M., et al. Central retinal vein occlusion in a young healthy COVID-19 patient: a case report and literature review. Middle East Afr. J. Ophthalmol. 2021;28(3):199&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763107</ArticleId><ArticleId IdType="pubmed">35125806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkenazy N., et al. Hemi- and central retinal vein occlusion associated with COVID-19 infection in young patients without known risk factors. Ophthalmol. Retin. 2022;6(6):520&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8907133</ArticleId><ArticleId IdType="pubmed">35278727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bapaye M.M., et al. Simultaneous bilateral central retinal artery occlusion following COVID-19 infection. Ocul. Immunol. Inflamm. 2021;29(4):671&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">33856275</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn A.P., Khurana R.N., Chang L.K. Hemi-retinal vein occlusion in a young patient with COVID-19. Am. J. Ophthalmol. Case Rep. 2021;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7932851</ArticleId><ArticleId IdType="pubmed">33688598</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaba W.H., et al. Bilateral central retinal vein occlusion in a 40-year-old man with severe coronavirus disease 2019 (COVID-19) pneumonia. Am. J. Case Rep. 2020;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603800</ArticleId><ArticleId IdType="pubmed">33116072</ArticleId></ArticleIdList></Reference><Reference><Citation>Invernizzi A., et al. Impending central retinal vein occlusion in a patient with Coronavirus disease 2019 (COVID-19) Ocul. Immunol. Inflamm. 2020;28(8):1290&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">32976055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilicarslan O., Cebi A.Y., Ucar D. Central retinal vein occlusion and occlusive vasculopathy at macula in a patient with recent COVID-19 infection. Taiwan J. Ophthalmol. 2022;12(4):477&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9843571</ArticleId><ArticleId IdType="pubmed">36660120</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller C.G., Kim B.J. Central retinal vein occlusion in a 46-year-old man with covID-19: case report and review of the literature. Case Rep. Ophthalmol. 2021;12(2):646&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8339514</ArticleId><ArticleId IdType="pubmed">34413756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad Hassan H., et al. Coronavirus Disease 2019 (COVID-19)- associated central retinal vein occlusion: a case report and literature review. Arch. Hematol. Case Rep. Rev. 2022;7(1):009&#x2013;012.</Citation></Reference><Reference><Citation>Montesel A., et al. Case report: central retinal artery occlusion in a COVID-19 patient. Front Pharm. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785811</ArticleId><ArticleId IdType="pubmed">33424598</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donovan C., Vyas N., Ghanchi F. Retinal vein occlusion with COVID-19: a case report and review of literature. Ocul. Immunol. Inflamm. 2022:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35119981</ArticleId></ArticleIdList></Reference><Reference><Citation>Raval N., Djougarian A., Lin J. Central retinal vein occlusion in the setting of COVID-19 infection. J. Ophthalmic Inflamm. Infect. 2021;11(1):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016503</ArticleId><ArticleId IdType="pubmed">33796944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheth J.U., et al. Retinal vein occlusion in COVID-19: a novel entity. Indian J. Ophthalmol. 2020;68(10):2291&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727974</ArticleId><ArticleId IdType="pubmed">32971697</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiroma H.F., et al. Retinal vascular occlusion in patients with the Covid-19 virus. Int J. Retin. Vitr. 2022;8(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9219213</ArticleId><ArticleId IdType="pubmed">35739568</ArticleId></ArticleIdList></Reference><Reference><Citation>Turedi N., Onal Gunay B. Paracentral acute middle maculopathy in the setting of central retinal artery occlusion following COVID-19 diagnosis. Eur. J. Ophthalmol. 2022;32(3):NP62&#x2013;NP66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111906</ArticleId><ArticleId IdType="pubmed">33583231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah I., et al. Central Retinal Vein Occlusion in patients with COVID-19 infection: a systematic review. Ann. Med Surg. (Lond. ) 2021;71</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500694</ArticleId><ArticleId IdType="pubmed">34659743</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesh R., et al. COVID-19-associated central retinal vein occlusion treated with oral aspirin. BMJ Case Rep. 2021;14(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137153</ArticleId><ArticleId IdType="pubmed">34011649</ArticleId></ArticleIdList></Reference><Reference><Citation>Walinjkar J.A., et al. Central retinal vein occlusion with COVID-19 infection as the presumptive etiology. Indian J. Ophthalmol. 2020;68(11):2572&#x2013;2574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7774137</ArticleId><ArticleId IdType="pubmed">33120696</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahalomi T., et al. Central retinal vein occlusion in a young healthy COVID-19 patient: a case report. Am. J. Ophthalmol. Case Rep. 2020;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668173</ArticleId><ArticleId IdType="pubmed">33225111</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Retinal artery/vein occlusion complicating SARS-CoV-2 vaccinations. J. Stroke Cereb. Dis. 2022;31(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9234003</ArticleId><ArticleId IdType="pubmed">35786536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonawane N.J., et al. Central retinal vein occlusion post-COVID-19 vaccination. Indian J. Ophthalmol. 2022;70(1):308&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8917569</ArticleId><ArticleId IdType="pubmed">34937265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Vigo J.I., et al. Bilateral retinal vein occlusion after two doses of SARS-CoV-2 adenovirus vector-based vaccine. J. Fr. Ophtalmol. 2022;45(9):e397&#x2013;e399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257142</ArticleId><ArticleId IdType="pubmed">36150989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegami Y., et al. Combined central retinal artery and vein occlusion shortly after mRNA-SARS-CoV-2 vaccination. QJM. 2022;114(12):884&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689963</ArticleId><ArticleId IdType="pubmed">34791479</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialasiewicz A.A., Farah-Diab M.S., Mebarki H.T. Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine. Int Ophthalmol. 2021;41(12):3889&#x2013;3892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8382109</ArticleId><ArticleId IdType="pubmed">34426861</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo B., Bahamon S., Martinez-Pulgarin D.F. Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: a case report. Indian J. Ophthalmol. 2021;69(10):2865&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597478</ArticleId><ArticleId IdType="pubmed">34571653</ArticleId></ArticleIdList></Reference><Reference><Citation>Werda S., et al. Occlusive retinal vasculopathy following AstraZeneca COVID-19 vaccination: a case report. J. Fr. Ophtalmol. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812823</ArticleId><ArticleId IdType="pubmed">36658069</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah P.P., et al. Central Retinal Vein Occlusion Following BNT162b2 (Pfizer-BioNTech) COVID-19 Messenger RNA Vaccine. Retin Cases Brief. Rep. 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">35025191</ArticleId></ArticleIdList></Reference><Reference><Citation>Pur D.R., Catherine L.L. Branch retinal vein occlusion in a healthy young man following mRNA COVID-19 vaccination. Am. J. Ophthalmol. Case Rep. 2022;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855639</ArticleId><ArticleId IdType="pubmed">35211659</ArticleId></ArticleIdList></Reference><Reference><Citation>Takacs A., Ecsedy M., Nagy Z.Z. Possible COVID-19 MRNA vaccine-induced case of unilateral central retinal vein occlusion. Ocul. Immunol. Inflamm. 2022:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35914296</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal M., Murthy S.I., Srinivas Y. Unilateral retinal vein occlusion in a young, healthy male following Sputnik V vaccination. Indian J. Ophthalmol. 2021;69(12):3793&#x2013;3794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837317</ArticleId><ArticleId IdType="pubmed">34827059</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujosevic S., et al. Retinal vascular occlusion and SARS-CoV-2 vaccination. Graefes Arch. Clin. Exp. Ophthalmol. 2022;260(11):3455&#x2013;3464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9130976</ArticleId><ArticleId IdType="pubmed">35612613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., et al. Combined central retinal artery and vein occlusion with ischemic optic neuropathy after COVID-19 vaccination. Int. Med. Case Rep. J. 2022;15:7&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778623</ArticleId><ArticleId IdType="pubmed">35079224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi P.K., et al. Central retinal vein occlusion following the first dose of COVID vaccine. Cureus. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9272389</ArticleId><ArticleId IdType="pubmed">35832754</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano D., et al. COVID-19 adenoviralvector vaccine and central retinal vein occlusion. Ocul. Immunol. Inflamm. 2022;30(5):1286&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">35653651</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.C. Combined central retinal artery occlusion and vein occlusion with exudative retinal detachment following COVID&#x2010;19 vaccination. Kaohsiung J. Med. Sci. 2022;38(10):1020&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538132</ArticleId><ArticleId IdType="pubmed">36098473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugihara K., Kono M., Tanito M. Branch retinal vein occlusion after messenger RNA-Based COVID-19 vaccine. Case Rep. Ophthalmol. 2022;13(1):28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832183</ArticleId><ArticleId IdType="pubmed">35221977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz O.A.G., Gonz&#xe1;lez-L&#xf3;pez J.J. Simultaneous unilateral central retinal vein occlusion and branch retinal artery occlusion after Coronavirus Disease 2019 (COVID-19) mRNA vaccine. Arq. Bras. De. Oftalmol. 2022;87(2)</Citation><ArticleIdList><ArticleId IdType="pubmed">36350909</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta Majumder P., Prakash V. Retinal venous occlusion following COVID-19 vaccination: report of a case after third dose and review of the literature. Indian J. Ophthalmol. 2022;70(6):2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359265</ArticleId><ArticleId IdType="pubmed">35648014</ArticleId></ArticleIdList></Reference><Reference><Citation>Girbardt C., et al. Retinal vascular events after mrnA and adenoviral-vectored COVID-19 vaccines-a case series. Vaccin. (Basel) 2021;9(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8625395</ArticleId><ArticleId IdType="pubmed">34835280</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdin A.D., Gartner B.C., Seitz B. Central retinal artery occlusion following COVID-19 vaccine administration. Am. J. Ophthalmol. Case Rep. 2022;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855623</ArticleId><ArticleId IdType="pubmed">35198832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow S.Y., Hsu Y.R., Fong V.H. Central retinal artery occlusion after Moderna mRNA-1273 vaccination. J. Formos. Med Assoc. 2022;121(11):2369&#x2013;2370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276520</ArticleId><ArticleId IdType="pubmed">35842300</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva L., et al. Vascular retinal findings after COVID-19 vaccination in 11 cases: a coincidence or consequence? Arq. Bras. Oftalmol. 2022;85(2):158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">35298583</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakar M., Bhattacharya S. Central retinal artery occlusion after vaccination with whole virion inactivated SARSCoV- 2 vaccine Covaxin. Indian J. Ophthalmol. 2022;70(10):3716&#x2013;3718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9789834</ArticleId><ArticleId IdType="pubmed">36190081</ArticleId></ArticleIdList></Reference><Reference><Citation>Karageorgiou G., et al. Branch retinal vein occlusion following ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. Eur. J. Ophthalmol. 2022 p. 11206721221124651.</Citation><ArticleIdList><ArticleId IdType="pubmed">36062592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi K., et al. Branch retinal artery occlusions, paracentral acute middle maculopathy and acute macular neuroretinopathy after COVID-19 vaccinations. Clin. Ophthalmol. 2022;16:987&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8980294</ArticleId><ArticleId IdType="pubmed">35392428</ArticleId></ArticleIdList></Reference><Reference><Citation>Groselli S., et al. [Retinal arteriovenous vascular occlusion after COVID vaccination with Vaxzevria(R) (AstraZeneca)-a complication of vaccination or not?] Ophthalmologie. 2022;119(12):1299&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8916693</ArticleId><ArticleId IdType="pubmed">35277744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolletta E., et al. Uveitis and other ocular complications following COVID-19 vaccination. J. Clin. Med. 2021;10(24)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8704915</ArticleId><ArticleId IdType="pubmed">34945256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H., et al. Exacerbation of branch retinal vein occlusion post SARS-CoV2 vaccination: case reports. Med. (Baltim. ) 2021;100(50)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677974</ArticleId><ArticleId IdType="pubmed">34918688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi R., et al. Retinal vein occlusion following two doses of mRNA-1237 (Moderna) immunization for SARS-Cov-2: a case report. Ophthalmol. Ther. 2022;11(1):453&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8654602</ArticleId><ArticleId IdType="pubmed">34881416</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley C., et al. Post-coronavirus disease 2019 (COVID-19) syndrome associated with central retinal vein occlusion: a case report. Ocul. Immunol. Inflamm. 2021:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">34637677</ArticleId></ArticleIdList></Reference><Reference><Citation>Rela M., et al. Auto-immune hepatitis following COVID vaccination. J. Autoimmun. 2021;123</Citation><ArticleIdList><ArticleId IdType="pubmed">34225251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow K.W., et al. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature. Dig. Dis. Sci. 2022;67(9):4574&#x2013;4580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9052185</ArticleId><ArticleId IdType="pubmed">35486203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani H., et al. Drug-induced hepatitis after Sinopharm COVID-19 vaccination: a case study of a 62-year-old patient. Int J. Surg. Case Rep. 2022;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906165</ArticleId><ArticleId IdType="pubmed">35284210</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido I., et al. Autoimmune hepatitis after COVID-19 vaccine - more than a coincidence. J. Autoimmun. 2021;125</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547941</ArticleId><ArticleId IdType="pubmed">34717185</ArticleId></ArticleIdList></Reference><Reference><Citation>Izagirre A., et al. Autoimmune hepatitis following COVID-19 vaccination. J. Autoimmun. 2022;132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9353598</ArticleId><ArticleId IdType="pubmed">35985054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zin Tun G.S., et al. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J. Hepatol. 2022;76(3):747&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491984</ArticleId><ArticleId IdType="pubmed">34619252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., et al. Autoimmune hepatitis after COVID-19 vaccination. Front Immunol. 2022;13:1035073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9732229</ArticleId><ArticleId IdType="pubmed">36505482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T., et al. New-onset autoimmune hepatitis following mRNA COVID-19 vaccination in a 36-year-old woman with primary sclerosing cholangitis - should we be more vigilant? J. Hepatol. 2022;76(1):218&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8384483</ArticleId><ArticleId IdType="pubmed">34450237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew M., et al. COVID-19 vaccine triggered autoimmune hepatitis: case report. Eur. J. Hosp. Pharm. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10447947</ArticleId><ArticleId IdType="pubmed">36207131</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuille-Lessard E., et al. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J. Autoimmun. 2021;123</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316013</ArticleId><ArticleId IdType="pubmed">34332438</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Navarro L., et al. In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID-19 vaccine-related hepatitis. J. Hepatol. 2023;78(1):e20&#x2013;e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9474959</ArticleId><ArticleId IdType="pubmed">36116717</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. A case report: long post-COVID vaccination syndrome during the eleven months after the third moderna dose. Cureus. 2022;14(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9833629</ArticleId><ArticleId IdType="pubmed">36644105</ArticleId></ArticleIdList></Reference><Reference><Citation>Finterer J., Scorza F.A. A retrospective analysis of clinically confirmed long post-COVID vaccination syndrome. J. Clin. Transl. Res. 2022;8(6):506&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9706319</ArticleId><ArticleId IdType="pubmed">36452006</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., et al. SARS-CoV-2 S1 protein persistence in SARS-CoV-2 negative post-vaccination individuals with long COVID/ PASC-like symptoms. Res. Sqare. 2022</Citation></Reference><Reference><Citation>Swissmedic. Verdachtsmeldungen unerw&#xfc;nschter Wirkungen der Covid-19 Impfungen in der Schweiz &#x2013; 29. Update. 2023 24 Befruary 2023]; Available from: &#x3008;https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/covid-19-vaccines-safety-update-19.html&#x3009;.</Citation></Reference><Reference><Citation>Wong T.L., Weitzer D.J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicines. 2021;57(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., et al. COVID-19 symptoms over time: comparing long-haulers to ME/CFS. Fatigue. 2021;9(2):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8411893</ArticleId><ArticleId IdType="pubmed">34484973</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokumasu K., et al. Clinical characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Diagnosed in patients with long COVID. Medicina. 2022;58(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325226</ArticleId><ArticleId IdType="pubmed">35888568</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Dorri J.A. ME/CFS and post-exertional malaise among patients with long COVID. Neurol. Int. 2022;15(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844405</ArticleId><ArticleId IdType="pubmed">36648965</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira C.R., et al. Improvement of Long COVID symptoms over one year. Front. Med. 2022;9:1065620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9868805</ArticleId><ArticleId IdType="pubmed">36698810</ArticleId></ArticleIdList></Reference><Reference><Citation>Manysheva K., et al. Myalgic encephalomyelitis/chronic fatigue syndrome: first described complication after gam-COVID-vac vaccine. Psychiatr. Danub. 2022;34(Suppl 8):189&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">36170726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gherardi R.K., Crepeaux G., Authier F.J. Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. Autoimmun. Rev. 2019;18(7):691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">31059838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12(570)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan Ali O., et al. Severe Coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) A and antiphospholipid IgA antibodies. Clin. Infect. Dis. 2021;73(9):e2869&#x2013;e2874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543315</ArticleId><ArticleId IdType="pubmed">32997739</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M., et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin. Exp. Rheuma. 2020;38(4):754&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">32723434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W., et al. COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity. J. Med Virol. 2023;95(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538121</ArticleId><ArticleId IdType="pubmed">36086941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallmann E., et al. IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients. J. Med Virol. 2023;95(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9877908</ArticleId><ArticleId IdType="pubmed">36324055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.E., et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 2021;12(1):5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst M.G.P., et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 2021;13(612):eabh2624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Koning R., et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021;47(6):704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034036</ArticleId><ArticleId IdType="pubmed">33835207</ArticleId></ArticleIdList></Reference><Reference><Citation>Briquez P.S., et al. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci. Adv. 2022;8(40):eabn3777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9544317</ArticleId><ArticleId IdType="pubmed">36206332</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers M.S., et al. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol. Cell Biol. 2021;99(9):917&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444766</ArticleId><ArticleId IdType="pubmed">34309902</ArticleId></ArticleIdList></Reference><Reference><Citation>Manry J., et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc. Natl. Acad. Sci. USA. 2022;119(21) p. e2200413119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173764</ArticleId><ArticleId IdType="pubmed">35576468</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Perez A.I., et al. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J. Autoimmun. 2021;122</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193025</ArticleId><ArticleId IdType="pubmed">34144328</ArticleId></ArticleIdList></Reference><Reference><Citation>Papola F., et al. Anti-AT1R autoantibodies and prediction of the severity of Covid-19. Hum. Immunol. 2022;83(2):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577881</ArticleId><ArticleId IdType="pubmed">34772541</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H., et al. Endothelial cell-activating antibodies in COVID-19. Arthritis Rheuma. 2022;74(7):1132&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082472</ArticleId><ArticleId IdType="pubmed">35174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagyas M., et al. The majority of severe COVID-19 patients develop anti-cardiac autoantibodies. Geroscience. 2022;44(5):2347&#x2013;2360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9483490</ArticleId><ArticleId IdType="pubmed">36112333</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., et al. Prevalence and characteristics of rheumatoid-associated autoantibodies in patients with COVID-19. J. Inflamm. Res. 2021;14:3123&#x2013;3128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286246</ArticleId><ArticleId IdType="pubmed">34285538</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K., et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur. Respir. J. 2023;61(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>L'Huillier A.G., et al. Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence. Eur. J. Clin. Invest. 2022;52(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348059</ArticleId><ArticleId IdType="pubmed">35598178</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C., et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav. Immun. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9841734</ArticleId><ArticleId IdType="pubmed">36657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D., et al. Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. Int J. Infect. Dis. 2021;113:23&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487460</ArticleId><ArticleId IdType="pubmed">34614444</ArticleId></ArticleIdList></Reference><Reference><Citation>Szewczykowski C., et al. Long COVID: association of functional autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation. Int. J. Mol. Sci. 2022;23(13)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9266742</ArticleId><ArticleId IdType="pubmed">35806214</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurner L., et al. Autoantibodies against SUMO1-DHX35 in long-COVID. J. Transl. Autoimmun. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9675633</ArticleId><ArticleId IdType="pubmed">36425003</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhorn R., et al. Autoantibody release in children after corona virus mRNA vaccination: a risk factor of multisystem inflammatory syndrome? Vaccines. 2021;9(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8618727</ArticleId><ArticleId IdType="pubmed">34835284</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank R.B., et al. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis. Rheumatol. (Oxf. ) 2022;62(1):467&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213868</ArticleId><ArticleId IdType="pubmed">35640110</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel E., et al. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis as a possible side effect of COVID-19 vaccination. Cureus. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9674930</ArticleId><ArticleId IdType="pubmed">36415412</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube G.K., Benvenuto L.J., Batal I. Antineutrophil cytoplasmic autoantibody&#x2013;associated glomerulonephritis following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int. Rep. 2021;6(12):3087&#x2013;3089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8372490</ArticleId><ArticleId IdType="pubmed">34423176</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito S., et al. A case of autoimmune hemolytic anemia following COVID-19 messenger ribonucleic acid vaccination. Cureus. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200779</ArticleId><ArticleId IdType="pubmed">34150386</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadi S.R.V., et al. Severe autoimmune hemolytic anemia following receipt of SARS&#x2010;CoV&#x2010;2 mRNA vaccine. Transfusion. 2021;61(11):3267&#x2013;3271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661722</ArticleId><ArticleId IdType="pubmed">34549821</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G., et al. A large cluster of new onset autoimmune myositis in the yorkshire region following SARS-CoV-2 vaccination. Vaccines. 2022;10(8):1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9331977</ArticleId><ArticleId IdType="pubmed">35893834</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bruyne S., et al. Life-threatening autoimmune hemolytic anemia following mRNA COVID-19 vaccination: don&#x2019;t be too prudent with the red gold. Clin. Chem. Lab. Med. (CCLM) 2022;60(6):e125&#x2013;e128.</Citation><ArticleIdList><ArticleId IdType="pubmed">35278047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghielmetti M., et al. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: a novel clinical entity? J. Autoimmun. 2021;123</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279947</ArticleId><ArticleId IdType="pubmed">34293683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T., et al. Detection of anti-GPIb&#x3b1; autoantibodies in a case of immune thrombocytopenia following COVID-19 vaccination. Thromb. Res. 2022;209:80&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648379</ArticleId><ArticleId IdType="pubmed">34894532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano M., et al. New-onset type 1 diabetes after COVID-19 mRNA vaccination. Intern. Med. 2022;61(8):1197&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107966</ArticleId><ArticleId IdType="pubmed">35135929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammami E., et al. Acquired thrombotic thrombocytopenic purpura after BNT162b2 COVID-19 vaccine: case report and literature review. Lab. Med. 2022;53(6):e145&#x2013;e148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129115</ArticleId><ArticleId IdType="pubmed">35482291</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamarti K., et al. Thrombotic thrombocytopenic purpura presentation in an elderly gentleman following COVID vaccine circumstances. Cureus. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381440</ArticleId><ArticleId IdType="pubmed">34447649</ArticleId></ArticleIdList></Reference><Reference><Citation>Raviv Y., et al. First presentation of systemic lupus erythematosus in a 24-year-old male following mRNA COVID-19 vaccine. Case Rep. Rheumatol. 2022;2022:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825270</ArticleId><ArticleId IdType="pubmed">35154842</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho-Dom&#xed;nguez L., et al. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature. J. Transl. Autoimmun. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8730708</ArticleId><ArticleId IdType="pubmed">35013724</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman D.S., et al. Acquired hemophilia A developed post COVID-19 Vaccine: an extremely rare complication. J. Med Cases. 2022;13(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8827248</ArticleId><ArticleId IdType="pubmed">35211227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekritthikrai K., et al. Autoimmune hepatitis triggered by COVID-19 vaccine: the first case from inactivated vaccine. ACG Case Rep. J. 2022;9(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246078</ArticleId><ArticleId IdType="pubmed">35784513</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama S., et al. First and fatal case of autoimmune acquired factor XIII/13 deficiency after COVID-19/SARS-CoV-2 vaccination. Am. J. Hematol. 2022;97(2):243&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011653</ArticleId><ArticleId IdType="pubmed">34856014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole A., et al. Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination. J. Autoimmun. 2022;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8888103</ArticleId><ArticleId IdType="pubmed">35247654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., et al. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol. Sci. 2021;42(9):3537&#x2013;3539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241205</ArticleId><ArticleId IdType="pubmed">34189662</ArticleId></ArticleIdList></Reference><Reference><Citation>Maronese C.A., et al. Bullous pemphigoid associated with COVID-19 vaccines: an italian multicentre study. Front Med (Lausanne) 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8918943</ArticleId><ArticleId IdType="pubmed">35295599</ArticleId></ArticleIdList></Reference><Reference><Citation>Prema J., et al. Two cases of double-positive antineutrophil cytoplasmic autoantibody and antiglomerular basement membrane disease after BBV152/covaxin vaccination. Kidney Int Rep. 2021;6(12):3090&#x2013;3091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513527</ArticleId><ArticleId IdType="pubmed">34660942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Saida I., et al. Acquired thrombotic thrombocytopenic purpura following inactivated COVID-19 vaccines: two case reports and a short literature review. Vaccines. 2022;10(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9319973</ArticleId><ArticleId IdType="pubmed">35891176</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthukumar A., et al. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine. Circulation. 2021;144(6):487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340727</ArticleId><ArticleId IdType="pubmed">34133883</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K., et al. Case of bullous pemphigoid following coronavirus disease 2019 vaccination. J. Dermatol. 2021;48(12):e606&#x2013;e607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652433</ArticleId><ArticleId IdType="pubmed">34545973</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurm C., et al. Homologous and heterologous anti-COVID-19 vaccination does not induce new-onset formation of autoantibodies typically accompanying lupus erythematodes, rheumatoid arthritis, celiac disease and antiphospholipid syndrome. Vaccin. (Basel) 2022;10(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8880348</ArticleId><ArticleId IdType="pubmed">35214790</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurm C., et al. Homologous and heterologous anti-COVID-19 vaccination does not induce new-onset formation of autoantibodies typically accompanying lupus erythematodes, rheumatoid arthritis, celiac disease and antiphospholipid syndrome. Vaccines. 2022;10(2):333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8880348</ArticleId><ArticleId IdType="pubmed">35214790</ArticleId></ArticleIdList></Reference><Reference><Citation>Noureldine H.A., et al. The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels. Immunol. Res. 2022;70(6):800&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385410</ArticleId><ArticleId IdType="pubmed">35978253</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschenbaum D., et al. Intracerebral endotheliitis and microbleeds are neuropathological features of COVID-19. Neuropathol. Appl. Neurobiol. 2021;47(3):454&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753688</ArticleId><ArticleId IdType="pubmed">33249605</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen L.A., et al. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 2020;20(7):389&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z. [Endotheliitis in COVID-19] Pathologe. 2020;41(Suppl 2):99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731145</ArticleId><ArticleId IdType="pubmed">33306138</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirican A., et al. The role of endotheliitis in COVID-19: Real-world experience of 11 190 patients and literature review for a pathophysiological map to clinical categorisation. Int. J. Clin. Pr. 2021;75(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646438</ArticleId><ArticleId IdType="pubmed">34519155</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberecker M., et al. Autopsy-based pulmonary and vascular pathology: pulmonary endotheliitis and multi-organ involvement in COVID-19 associated deaths. Respiration. 2022;101(2):155&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8678227</ArticleId><ArticleId IdType="pubmed">34525475</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadpour M., Farrokhpour H., Sadeghi R. Herpetic endotheliitis and stromal keratitis following inactivated COVID-19 vaccination. Clin. Case Rep. 2022;10(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9536498</ArticleId><ArticleId IdType="pubmed">36237947</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkwikbi H., et al. Herpetic keratitis and corneal endothelitis following COVID-19 vaccination: a case series. Cureus. 2022;14(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815810</ArticleId><ArticleId IdType="pubmed">35154946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J. Clin. Invest. 2022;132(15)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 2021;19(10):2546&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto V., et al. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front Immunol. 2022;13:1070379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9798841</ArticleId><ArticleId IdType="pubmed">36591311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., et al. COVID-19 and cognitive impairment: neuroinvasive and blood-brain barrier dysfunction. J. Neuroinflamm. 2022;19(1):222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9450840</ArticleId><ArticleId IdType="pubmed">36071466</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., et al. The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Rep. 2022;17(2):307&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8772030</ArticleId><ArticleId IdType="pubmed">35063125</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastogi A., et al. Reversible neurological and brain MRI changes following COVID-19 vaccination: a case report. J. Neuroradiol. 2022;49(6):428&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976577</ArticleId><ArticleId IdType="pubmed">35381296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral G., et al. MRI negative myelitis induced by Pfizer-BioNTech COVID-19 vaccine. J. Clin. Neurol. 2022;18(1):120&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8762507</ArticleId><ArticleId IdType="pubmed">35021291</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldelli L., et al. Hyperacute reversible encephalopathy related to cytokine storm following COVID-19 vaccine. J. Neuroimmunol. 2021;358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8275470</ArticleId><ArticleId IdType="pubmed">34284342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., et al. Prevalence of readily detected amyloid blood clots in 'unclotted' Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovasc Diabetol. 2020;19(1):193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20(1):172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A., et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21(1):190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479(4):537&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) Cardiovasc. Diabetol. 2022;21(1):148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Pan J.Y. Anatomical and pathological observation and analysis of SARS and COVID-19: microthrombosis is the main cause of death. Biol. Proced. Online. 2021;23(1):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816139</ArticleId><ArticleId IdType="pubmed">33472576</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra-Medina R., Herrera S., Mejia J. Systematic review of microthrombi in COVID-19 autopsies. Acta Haematol. 2021;144(5):476&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8089413</ArticleId><ArticleId IdType="pubmed">33873184</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese A., et al. Autopsy findings in COVID-19-related deaths: a literature review. Forensic Sci. Med Pathol. 2021;17(2):279&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538370</ArticleId><ArticleId IdType="pubmed">33026628</ArticleId></ArticleIdList></Reference><Reference><Citation>Menezes R.G., et al. Postmortem findings in COVID-19 fatalities: a systematic review of current evidence. Leg. Med. 2022;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648585</ArticleId><ArticleId IdType="pubmed">34952452</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanni D., et al. Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: a report of an autoptic case and review of the literature. Eur. Rev. Med Pharm. Sci. 2021;25(15):5063&#x2013;5069.</Citation><ArticleIdList><ArticleId IdType="pubmed">34355379</ArticleId></ArticleIdList></Reference><Reference><Citation>Althaus K., et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica. 2021;106(8):2170&#x2013;2179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8327736</ArticleId><ArticleId IdType="pubmed">34011137</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa T., et al. Myocardial microthrombi after COVID-19 mRNA vaccination. Eur. Heart J. 2021;42(43):4501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8599010</ArticleId><ArticleId IdType="pubmed">34624077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang M.S., Kim S.Y., Kwon H.J. Case report: recanalization of branch retinal artery occlusion due to microthrombi following the first dose of SARS-CoV-2 mRNA vaccination. Front Pharm. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988066</ArticleId><ArticleId IdType="pubmed">35401231</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S., Choi B.-H. Acute myocardial infarction with microthrombi in cardiac small vessels after COVID-19 vaccination (ChAdOx1 nCov-19): a case report. Korean J. Leg. Med. 2021;45(4):127&#x2013;132.</Citation></Reference><Reference><Citation>Chang J.C., Hawley H.B. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to venous combined micro-macrothrombosis. Medicina. 2021;57(11):1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8621006</ArticleId><ArticleId IdType="pubmed">34833382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramessur R., et al. Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination. Clin. Exp. Dermatol. 2021;46(8):1610&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444634</ArticleId><ArticleId IdType="pubmed">34189756</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzun G., et al. Organ donation from a brain dead donor with vaccine-induced immune thrombotic thrombocytopenia after Ad26.COV2.S: the risk of organ microthrombi. Transplantation. 2022;106(3):e178&#x2013;e180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862669</ArticleId><ArticleId IdType="pubmed">34974451</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomara C., et al. Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica. 2021;106(8):2291&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8327725</ArticleId><ArticleId IdType="pubmed">34011138</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C., et al. Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. J. Med Virol. 2023;95(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878213</ArticleId><ArticleId IdType="pubmed">36458566</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z., et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin. Infect. Dis. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram-Mohan N., et al. SARS-CoV-2 RNAemia predicts clinical deterioration and extrapulmonary complications from COVID-19. Clin. Infect. Dis. 2022;74(2):218&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135992</ArticleId><ArticleId IdType="pubmed">33949665</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram-Mohan N., et al. Association between SARS-CoV-2 RNAemia and postacute sequelae of COVID-19. Open Forum Infect. Dis. 2022;9(2):ofab646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8802799</ArticleId><ArticleId IdType="pubmed">35111870</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V., et al. Persistent circulation of soluble and extracellular vesicle&#x2010;linked Spike protein in individuals with postacute sequelae of COVID&#x2010;19. J. Med. Virol. 2023;95(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh D., et al. Case report: persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9483160</ArticleId><ArticleId IdType="pubmed">36131932</ArticleId></ArticleIdList></Reference><Reference><Citation>Castruita J.A.S., et al. SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination. APMIS. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10107710</ArticleId><ArticleId IdType="pubmed">36647776</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal S., et al. Cutting edge: circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to development of antibodies: a novel mechanism for immune activation by mRNA vaccines. J. Immunol. 2021;207(10):2405&#x2013;2410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11073804</ArticleId><ArticleId IdType="pubmed">34654691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fertig T.E., et al. Vaccine mRNA can be detected in blood at 15 days post-vaccination. Biomedicines. 2022;10(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9313234</ArticleId><ArticleId IdType="pubmed">35884842</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata A.F., et al. Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin. Infect. Dis. 2022;74(4):715&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241425</ArticleId><ArticleId IdType="pubmed">34015087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker L.M., et al. Circulating spike protein detected in Post-COVID-19 mRNA vaccine myocarditis. Circulation. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10010667</ArticleId><ArticleId IdType="pubmed">36597886</ArticleId></ArticleIdList></Reference><Reference><Citation>Coly M., et al. Subacute monomelic radiculoplexus neuropathy following Comirnaty(c) (Pfizer-BioNTech COVID-19) vaccination: A case report. Rev. Neurol. (Paris) 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10012230</ArticleId><ArticleId IdType="pubmed">36925320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna N., et al. Detection of messenger RNA COVID-19 vaccines in human breast milk. JAMA Pedia. 2022;176(12):1268&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513706</ArticleId><ArticleId IdType="pubmed">36156636</ArticleId></ArticleIdList></Reference><Reference><Citation>Low J.M., et al. Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees. NPJ Vaccin. 2021;6(1):105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8376902</ArticleId><ArticleId IdType="pubmed">34413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Golan Y., et al. Evaluation of messenger RNA from COVID-19 BTN162b2 and mRNA-1273 vaccines in human milk. JAMA Pedia. 2021;175(10):1069&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261686</ArticleId><ArticleId IdType="pubmed">34228115</ArticleId></ArticleIdList></Reference><Reference><Citation>Egwang T.G. Evaluating COVID-19 vaccine-related messenger RNA in breast milk. JAMA Pedia. 2022;176(1):99&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">34661603</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltgen K., et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185(6):1025&#x2013;1040 e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Nance K.D., Meier J.L. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci. 2021;7(5):748&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043204</ArticleId><ArticleId IdType="pubmed">34075344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rzymski P., Fal A. To aspirate or not to aspirate? Considerations for the COVID-19 vaccines. Pharm. Rep. 2022;74(6):1223&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941363</ArticleId><ArticleId IdType="pubmed">35320581</ArticleId></ArticleIdList></Reference><Reference><Citation>Naasani I. Establishing the pharmacokinetics of genetic vaccines is essential for maximising their safety and efficacy. Clin. Pharm. 2022;61(7):921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">35821373</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., et al. Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in mouse model. Clin. Infect. Dis. 2022;74(11):1933&#x2013;1950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436386</ArticleId><ArticleId IdType="pubmed">34406358</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolai L., et al. Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration. Blood. 2022;140(5):478&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060731</ArticleId><ArticleId IdType="pubmed">35486845</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino M., Marino F. Understanding the pharmacology of COVID-19 mRNA vaccines: playing dice with the spike? Int J. Mol. Sci. 2022;23(18)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9502275</ArticleId><ArticleId IdType="pubmed">36142792</ArticleId></ArticleIdList></Reference><Reference><Citation>McKernan K., et al. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose. OSFPREPRINTS. 2023</Citation></Reference><Reference><Citation>Krutzke L., et al. Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine. eLife. 2022;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9313527</ArticleId><ArticleId IdType="pubmed">35781137</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano G., et al. Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA. Future Virol. 2022;17(3):191&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647997</ArticleId><ArticleId IdType="pubmed">34887937</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA . European Medicines Agency; 2021. Asessemtn report - COVID-19 vaccine Moderna. Procedure No. EMEA/H/C/005791/0000.</Citation></Reference><Reference><Citation>EMA . European Medicines Agency; 2021. Assessment report - Comirnaty. Procedure No. EMEA/H/C/005735/0000.</Citation></Reference><Reference><Citation>Krantz M.S., et al. COVID-19 vaccine anaphylaxis: PEG or not? Allergy. 2021;76(6):1934&#x2013;1937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441754</ArticleId><ArticleId IdType="pubmed">34128562</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellaturay P., et al. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin. Exp. Allergy. 2021;51(6):861&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251011</ArticleId><ArticleId IdType="pubmed">33825239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanillas B., Akdis C.A., Novak N. COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?". Allergy. 2021;76(6):1938&#x2013;1940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441702</ArticleId><ArticleId IdType="pubmed">34128561</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson L., et al. Vaccine allergy: evidence to consider for COVID-19 vaccines. Curr. Opin. Allergy Clin. Immunol. 2021;21(4):401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270228</ArticleId><ArticleId IdType="pubmed">34091550</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimek L., et al. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy. 2021;76(11):3307&#x2013;3313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013891</ArticleId><ArticleId IdType="pubmed">33657648</ArticleId></ArticleIdList></Reference><Reference><Citation>McSweeney M.D., et al. Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy. Front Allergy. 2021;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8974707</ArticleId><ArticleId IdType="pubmed">35387046</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvey L.H., Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br. J. Anaesth. 2021;126(3):e106&#x2013;e108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834677</ArticleId><ArticleId IdType="pubmed">33386124</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrini G., et al. Monitoring Anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration. Int J. Mol. Sci. 2022;23(16)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9408675</ArticleId><ArticleId IdType="pubmed">36012103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelso J.M. IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines. Clin. Exp. Allergy. 2022;52(1):10&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444836</ArticleId><ArticleId IdType="pubmed">34318537</ArticleId></ArticleIdList></Reference><Reference><Citation>Azenha Rama T., et al. Hypersensitivity to the moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient. J. Invest. Allergol. Clin. Immunol. 2022;32(5):414&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">34924354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanillas B., Akdis C.A., Novak N. COVID-19 vaccines and the role of other potential allergenic components different from PEG. A reply to: "other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines". Allergy. 2021;76(6):1943&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441644</ArticleId><ArticleId IdType="pubmed">34128563</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgsteede S.D., Geersing T.H., Tempels-Pavlica Z. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines. Allergy. 2021;76(6):1941&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441744</ArticleId><ArticleId IdType="pubmed">34128559</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers E.L. Recursive debility: symptoms, patient activism, and the incomplete medicalization of ME/CFS. Med. Anthropol. Q. 2022;36(3):412&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">35262958</ArticleId></ArticleIdList></Reference><Reference><Citation>Blease C., Geraghty K.J. Are ME/CFS patient organizations "militant"?: Patient protest in a medical controversy. J. Bioeth. Inq. 2018;15(3):393&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">29971693</ArticleId></ArticleIdList></Reference><Reference><Citation>Au L., et al. Long covid and medical gaslighting: dismissal, delayed diagnosis, and deferred treatment. SSM Qual. Res Health. 2022;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9448633</ArticleId><ArticleId IdType="pubmed">36092770</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan N.A. The teachings of long COVID. Commun. Med (Lond. ) 2021;1:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9053272</ArticleId><ArticleId IdType="pubmed">35602198</ArticleId></ArticleIdList></Reference><Reference><Citation>Perego E., et al. Why the Patient-Made Term 'Long Covid' is needed. Wellcome Open Res. 2020;5:224.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>